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Neglected tropical diseases (NTDs) are a major economic 
and health burden in developing countries across the world, 
affecting more than 1 billion people worldwide.1–3 This 
broad group of diseases encompasses a range of viral, bac-
terial, and parasitic infections, determined as neglected 
based on the lack of investment they receive in relation to 
the “big three” infectious diseases (tuberculosis, HIV/
AIDS, and malaria).2 Despite the huge worldwide burden, 
this lack of investment has resulted in limited development 
of new drugs to treat these diseases.1,4 Although the veteri-
nary drug moxidectin has recently been approved for the 
treatment of onchocerciasis, the lack of any new chemical 
entity approved for use against helminth infections in the 
past decade clearly highlights this issue.4,5
Lymphatic filariasis (LF) and onchocerciasis are two 
NTDs that are both caused by helminthic infections with 
filarial nematodes. These diseases are leading causes of 
global morbidity,2,6 but currently there are only three drugs 
suitable for mass drug administration (MDA): ivermectin 
(IVM), albendazole (ALB), and diethylcarbamazine citrate 
(DEC). The main limitation of these drugs is that they prin-
cipally target the larval stage of these parasites (microfilar-
iae).3,7 Microfilaricidal drugs interrupt transmission to the 
insect vectors and alleviate the symptoms of onchocerciasis. 
However, the adult parasites are able to repopulate 
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Abstract
The Anti-Wolbachia (A·WOL) consortium at the Liverpool School of Tropical Medicine (LSTM) has partnered with the 
Global High-Throughput Screening (HTS) Centre at AstraZeneca to create the first anthelmintic HTS for neglected tropical 
diseases (NTDs). The A·WOL consortium aims to identify novel macrofilaricidal drugs targeting the essential bacterial 
symbiont (Wolbachia) of the filarial nematodes causing onchocerciasis and lymphatic filariasis. Working in collaboration, 
we have validated a robust high-throughput assay capable of identifying compounds that selectively kill Wolbachia over the 
host insect cell. We describe the development and validation process of this complex, phenotypic high-throughput assay 
and provide an overview of the primary outputs from screening the AstraZeneca library of 1.3 million compounds.
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microfilarial loads, requiring sustained long-term treatment 
delivery to cover their reproductive life span.8 This limita-
tion is compounded by concerns over potential drug resis-
tance9 and the risk of severe adverse events (SAEs) in 
settings co-endemic with Loa loa (IVM and DEC) and 
onchocerciasis (DEC).
An alternative approach, which overcomes these limita-
tions, is to target the essential endosymbiont, Wolbachia, 
which has evolved a mutualism with the parasites that cause 
onchocerciasis and LF.10
A 4- to 6-week course of doxycycline eliminates the 
Wolbachia endosymbionts, leading to an effective macro-
filaricidal (death of the adult worm) activity.11–14 
Additionally, embryogenesis is blocked and microfilariae 
development is impaired in the vector,15 resulting in a com-
plete block in transmission.3 Furthermore, as this bacterial 
target is not present in Loa loa, there is no risk of SAE, 
allowing for safe use in these co-endemic areas. Barriers to 
the wide-scale use of doxycycline as a macrofilaricidal 
treatment are the limitations of the long treatment period 
(4–6 weeks) and contraindications in pregnant women and 
children.
In the context of aiming to achieve the WHO targets of 
eliminating LF and onchocerciasis, Wolbachia as the drug 
target provides a promising new angle; however, new drugs 
are required (with no contraindications and a shorter treat-
ment regime).2,3 The Anti-Wolbachia (A·WOL) consortium 
was established to meet this challenge. Recent drug discov-
ery successes have relied heavily on collaboration and 
access to large compound libraries,1,4 with large pharma-
ceutical companies ever more open to partner in areas of 
clear unmet medical need.16–18
The complex biology and life cycle involved in LF and 
onchocerciasis has made industrial-scale drug discovery 
programs extremely challenging;19 however, the A·WOL 
consortium started to address these challenges through the 
development and deployment of an in vitro assay system 
employing an insect cell line stably infected with 
Wolbachia.2,7,20,21 Use of this system was central to the 
development of a drug discovery program that has already 
tested a variety of compound libraries from a range of 
sources, through multiple collaborations.7,21,22 This paper 
describes an innovative new collaboration between A·WOL 
and AstraZeneca that has allowed the first truly open-access 
collaboration between academia and industry, in the anthel-
mintic field.2,20 This partnership has taken collaborations a 
step further than the simple sharing of a compound library 
with a group already running screens against a particular 
molecular target or phenotype. Through this open-access 
collaboration scientists from A·WOL with knowledge of the 
disease biology and current screening assays against 
Wolbachia were given full access to the AstraZeneca com-
pound library and laboratory facilities. This included access 
to specialist automation and internal expertise in the field of 
high-throughput screening (HTS). The collaboration culmi-
nated in the development, validation, and execution of a 
novel industrial-scale HTS against 1.3 million compounds, 
the largest of its kind ever completed against any anthel-
mintic NTD. Details of the completion, follow-up studies, 
and subsequent identification of five series of fast-acting 
macrofilaricides have been presented in Clare et al. (2019).23
Materials and Methods
Cell Culture
The C6/36 (wAlbB) cell line used in this screen has been 
described previously.2,7,20–23 In brief this mosquito (Aedes 
albopictus)-derived cell line is stably infected with Wolbachia 
pipientis (wAlbB). For use in the screen, cells were cultured 
in Leibovitz medium (Life Technologies)[AQ: 1] supple-
mented with 20% fetal bovine serum (FBS; Fisher 
Scientific), 2% tryptose phosphate broth (Sigma-Aldrich), 
1% nonessential amino acids (Sigma-Aldrich), and 1% pen-
icillin-streptomycin (Sigma-Aldrich) at 26 °C, without 
additional CO2. The medium described was optimized 
through previous work.20
Large-Scale Cryopreserved Cell Bank
C6/36 (wAlbB) cells were cultured at scale in 16 T225 cm2 
flasks (Thermo Fisher) to generate 6.16 × 109 cells after 7 
days of incubation. To produce the cryopreserved cell bank, 
spent medium was removed and replaced with 20 mL of 
fresh cell culture medium. The cells were detached by 
scraping, combined, and centrifuged. The pellet was resus-
pended in cryopreservation medium (90% FBS and 10% 
DMSO) to a density of 3 × 107 cells/mL. The cells were 
aliquoted 1 mL per cryovial for cryopreservation using a 
control rate freezer (Planar Kryo 560-16). This resulted in a 
cryopreserved cell bank of 190 vials.
Cell Bank Recovery and Quality Control  
for Screening
A single cryovial was recovered by defrosting at 37 °C for 
45 s, followed by immediate resuspension in 40 mL of 
cell culture medium, resulting in a DMSO concentration 
of <0.25%. The cells were centrifuged and resuspended 
in 45 mL of cell culture medium in a T225 cm2 flask 
(VWR). After a 7-day incubation at 26 °C, with ambient 
CO2, the cells were tested (quality control [QC]) for 
Wolbachia infection levels by adding 40 μL of the resus-
pended cells to a 384-well, black, clear-bottom, tissue 
culture-treated plate (781090, Greiner Bio-One). Once 
settled, the cells were fixed for 20 min with formaldehyde 
(0.82% final concentration) supplemented with Hoechst 
33342 (54 µg/mL final concentration, Life Technologies). 
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A phosphate-buffered saline (PBS) wash was followed by 
incubation with SYTO 11 for 15 min (7.5 μM final con-
centration, Life Technologies). After a final PBS wash, 
the cells were left in PBS and analyzed on the PerkinElmer 
Operetta cellular imaging system, to assess the percent-
age of cells infected with Wolbachia. Confocal images 
were acquired using a 60× objective and the cell nuclei 
identified using the Hoechst stain, allowing for the cyto-
plasm (omitting the nucleus) to be located by the SYTO 
11 staining. As previously reported by Clare et al. 
(2014),20 the cytoplasm texture was analyzed (with a 
more granular texture indicating a higher Wolbachia 
infection level). Based on image analysis of infected and 
uninfected cells, a threshold was set at a texture score of 
0.0028, within the PerkinElmer Harmony analysis soft-
ware. Above this threshold cells were classed as infected 
with Wolbachia, and those cultures with greater than 50% 
of the cell population infected were deemed to have 
passed QC and were subsequently used for screening.
Compound Handling
Compounds sourced from the AstraZeneca library were 
plated from liquid stock (held at 10 mM in 100% DMSO 
and stored in 1536-well microtiter plates). For single-shot 
screening, 80 nL of this stock was dispensed into each well 
of a 384-well, clear-bottom microtiter plate (781090, 
Greiner Bio-One) via acoustic drop ejection (using Labcyte 
Echo 555 liquid handling units) to create assay-ready plates 
(ARPs). Once diluted through addition of 80 µL of cell sus-
pension this would yield a final screening concentration of 
10 µM. Onboard maximum/minimum controls were 
included on each ARP in two central columns, resulting in 
16 wells of each control (containing 80 nL of either 100% 
DMSO or 5 mM doxycycline, respectively). Concentration–
response curves for assay concordance testing and valida-
tion were also built using the Labcyte Echo 555 units, with 
a final dose range—following the addition of 80 µL of cell 
suspension—of 30 µM to 20 pM (across 13 points, using 
half-log dilutions). These compounds were selected and 
sourced from A·WOL compound libraries at a stock con-
centration of 10 mM in 100% DMSO. In order to create the 
30 µM concentration point from a 10 mM stock, the volume 
of compound dispensed for these specific wells was 
increased to 240 nL (meaning that the DMSO concentration 
in the top dose points was three times higher than across the 
remainder of the compound curves).
Additional QC plates—containing only control wells—
were interspersed into the screening runs. These plates 
included columns of “Max signal” (100% DMSO), “Min 
signal” (5 mM doxycycline), and “Reference signal” 
(50 µM doxycycline) repeated across the plate and were 
built in the same way as the ARPs, using the Labcyte Echo 
555 units.
Wolbachia Specific Primary Antibody 
Production
The antibody was made by Covance as previously 
described24,25 by immunizing five specific pathogen-free 
(SPF) rabbits with Wolbachia peptidoglycan-associated 
lipoprotein from Brugia malayi (wBmPAL) produced by 
New England BioLabs (NEB). The antiserum was obtained 
and the anti-wBmPAL antibody purified by affinity column 
chromatography. From this we gained 350 mL of antibody, 
which we titrated against various concentrations of the sec-
ondary antibody, Alexa Fluor 680 goat anti-rabbit IgG 
(A-21076, far red fluorescence, Life Technologies).
Detection (acumen Explorer eX3 
Analysis) and EnVision Read
The TTP acumen Explorer eX3 adherent cell cytometer 
(referred to from this point as “acumen”) was configured 
using a 633 nm excitation laser (via a 633 nm dichroic mir-
ror) and Wolbachia fluorescence was detected by a 655 nm 
long pass filter (655–800 nm filter) (Suppl. Fig. S1). The 
acumen analysis software identified objects, based on sepa-
rate areas of fluorescence, which were subsequently gated 
for excessive area and fluorescence intensity. The total area 
of the filtered objects (assumed to be cytoplasm-encapsu-
lated Wolbachia) per well was calculated as the readout. 
This gave quantification of Wolbachia levels per well, 
where compounds with anti-Wolbachia activity were repre-
sented by a decreased total area per well.
As this decrease in area of Wolbachia fluorescence 
would also occur if the compounds showed host cell toxic-
ity (low number of cells either with or without a Wolbachia 
infection), a cell toxicity read was included to identify such 
“false positives.” To optimize throughput, this toxicity read 
was carried out by a single fluorescent readout per well, 
based on the intensity of Hoechst staining, detected via a 
PerkinElmer EnVision plate reader. The EnVision was opti-
mized using a bottom mirror with 355/103 nm excitation 
and 460/207 nm emission filters (set to 10 flashes per read). 
The acumen acquisition and analysis step was processed in 
approximately 20 min, while the EnVision read was 
obtained in 2 min. This total screening time of 22 min per 
plate allowed for a full run of 150 plates to be read in 55 h. 
To increase the throughput further, two acumen units and a 
single EnVision unit were utilized, allowing for the 150-
plate batch to be read in 28 h.
Validation of the HTS Assay
The assay was robustly validated, following AstraZeneca’s 
established process.
AstraZeneca holds a validation set of 7000 compounds 
(representing the full library), which are run on at least two 
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occasions against the assay (nominally termed occasion 1 
and occasion 2). In addition, each occasion comprises two 
different physical picks of compounds from the AstraZeneca 
compound store. Each of these physical picks of compounds 
is plated in a different order and thus allows validation 
against inter- and intraplate variation within a given assay.
Each occasion of the AstraZeneca validation set testing 
took place on a separate experimental run at a single con-
centration (10 µM final concentration). Each experiment 
used a different cryopreserved cell population and freshly 
made reagents (mimicking a true experimental run as 
closely as possible). Alongside this “generic” validation set, 
20 compounds were selected from the A·WOL drug discov-
ery program, spanning various levels of both anti-Wolba-
chia activity and host cell toxicity. These compounds 
(including the well-characterized tetracycline doxycycline) 
were run in concentration response. The IC50 values gener-
ated were compared to those calculated previously in imag-
ing assays from A·WOL using a PerkinElmer Operetta.20–22
Screening Protocol
An overview of the 3-week screening protocol is presented 
in Supplemental Figure S2. On the morning of each 
screening run, cells recovered from a cryovial 7 days previ-
ously were QC checked for confluence and Wolbachia 
infection levels (as described earlier). The cells were 
counted on a Vi-Cell XR (Beckman Coulter) and diluted to 
a concentration of 25,000 cells/mL in assay medium (as cul-
ture medium described earlier). Compound plates were 
organized into batches of around 150, including 2 “max” 
plates (maximum signal, no compounds or DMSO added) 
at the beginning of each run and 3 QC plates (as described 
earlier) dispersed throughout the run. Using a Multidrop 
Combi (Thermo Scientific), 80 μL of cell suspension was 
added to each test well, resulting in a seeding density of 
2000 cells per well. All plates were foil sealed using a 
PlateLoc thermal plate sealer (Velocity11) for 2 s at 230 °C, 
and incubated for 7 days at 26 °C, with ambient CO2. In 
addition to the screening plates, a single max plate was cre-
ated with a clear seal in order to periodically monitor the 
cell growth over the 7 days, without having to disturb any 
assay plates.
On day 7 post cell dispense, the assay plates were loaded 
into the incubator (Liconic) on a BioCel 1800 automation 
system (Agilent Technologies) held at 26 °C, with ambient 
CO2. To enable the assay staining protocol, the BioCel sys-
tem was configured with five Multidrop Combis (Thermo 
Scientific), two plate washers (PW 384, Tecan), three 
robotic arms, one plate carousel, one PlateLoc thermal plate 
sealer (Velocity11), and one automated plate seal remover 
(XPeel, Brooks) (Suppl. Fig. S3). Using this platform 
under the control of Agilent Vworks software, plates were 
allowed to enter the system every 2 min. The plates were 
fixed by adding 20 μL of 9% formaldehyde containing 
3 µg/mL of Hoechst 33342 (Life Technologies) directly into 
each well containing 80 μL of cell culture, using one of the 
Multidrop Combis (1.8% final formaldehyde concentration 
and 0.6 µg/mL Hoechst), for 20 min. The fixative was aspi-
rated off using the Tecan PW, and following this 80 μL of 
PBS was dispensed into each well using a Multidrop Combi. 
The PBS was aspirated off using the Tecan PW and the 
adherent cells were permeabilized by the addition of 80 μL 
of PBS + 0.25% Triton-X 100 (Sigma-Aldrich) using a 
Multidrop Combi. Following a 30 min incubation at room 
temperature with the permeabilization buffer, a further 80 
μL of PBS wash was performed. The plates were blocked 
with the addition of 80 μL of blocking buffer (PBS + 6% 
bovine serum albumin [BSA] [Sigma-Aldrich]) for 40 min 
at room temperature, before removal of the blocking buffer 
by aspiration on the Tecan PW and addition of the anti-pep-
tidoglycan-associated lipoprotein from the Wolbachia of 
the filarial nematode Brugia malayi (wBmPAL) primary 
antibody (in PBS + 6% BSA), using one of the Multidrop 
Combis (30 µL of 1:2000 dilution in blocking buffer). 
Primary antibody was incubated for 12 h at room tempera-
ture, before unbound antibody was removed by aspiration 
on the Tecan PW followed by addition of 80 µL of wash 
buffer (PBS + 0.05% polysorbate [Sigma-Aldrich]) and 
incubation at room temperature for 6 min. Following aspi-
ration of the wash buffer, addition of the Alexa Fluor 680 
goat anti-rabbit (A-21076, Life Technologies) secondary 
antibody (30 µL of 1:400 dilution in blocking buffer) was 
performed with a third Multidrop Combi and plates were 
incubated for 1 h at room temperature. Following this incu-
bation, the secondary antibody was removed with 2× 80 
µL, 6 min PBS + 0.05% polysorbate washes (as described 
earlier for the primary antibody) and plates left with 40 μL 
of PBS per well. As a final step, the assay plates were foil 
sealed (using the PlateLoc at 170 °C for 1 s) and output to 
stacker units on the BioCel platform (Suppl. Fig. S3).
The fixed antibody-stained plates were read on a 
PerkinElmer EnVision (Hoechst host cell toxicity analysis) 
and subsequently a TTP acumen (Wolbachia analysis), both 
automated via a HighRes Biosolutions Dual pod six-sided 
MicroStar under the control of Cellario scheduling software 
(Suppl. Fig. S4).
Data Analysis
Genedata Screener was used for all data analysis. Readouts 
from both the acumen and EnVision were imported into 
Screener, in which data for toxicity (Hoechst read on the 
EnVision) and anti-Wolbachia activity (Wolbachia area 
detected on the acumen) were normalized on an individual 
plate basis. For single-concentration primary screening, the 
toxicity read was normalized to the median read from all 
compounds on each plate as it is assumed that (1) toxic 
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compounds are randomly distributed over the plates in a 
given screening run, and (2) toxicity against the insect cell 
line should be limited within the AstraZeneca collection. 
The plate median is therefore taken to represent a “Max 
Hoechst signal” (0% toxicity toward the host insect cell). 
The anti-Wolbachia reads were normalized against the Max 
signal (DMSO control wells) and Min signal (5 μM doxy-
cycline wells)—taken to represent 0% and 100% anti- 
Wolbachia activity, respectively.
The data were processed to identify “hits” (anti-Wolba-
chia activity) that presented little or no toxicity to the host 
cell line. To do this, the normalized anti-Wolbachia data 
were cut at ≥80% inhibition and the compounds falling 
above this cut were further annotated to identify those with 
≤60% cytotoxic effect on the C6/36 host cell line.
Additionally, all plates were monitored for Z′, robust Z 
score, and signal to background. These data were analyzed 
on a per-plate basis within each run so we could flag up and 
repeat plates that did not pass our acceptance criteria, but 
also across all runs in the completed screen to follow reli-
ability and identify any potential adverse data trends.
Results and Discussion
To establish a screening assay suitable for the delivery of an 
HTS campaign, we built upon the shared knowledge and 
experience of both A·WOL and AstraZeneca. Taking the 
C6/36 (wAlbB) cell line and Wolbachia specific antibody 
described previously,24,25 we built and validated an assay on 
the TTP acumen Explorer eX3 adherent cytometer plat-
form. This platform has many advantages over traditional 
imaging platforms in the high-throughput setting (primarily 
driven by speed of whole-well acquisition, combined with 
low data burden per scan). In the context of this screen, we 
did not require the resolution of a true imaging platform in 
order to give us spatial information, but rather needed a 
gross measure of Wolbachia number across the whole test 
well.
Although the C6/36 (wAlbB) line has been used for 
smaller-scale screening activities previously within 
A·WOL, experience with this cell line has also shown that 
Wolbachia infection levels can fluctuate over extended peri-
ods of continuous culture. For this reason, we invested time 
early in the assay development process, to produce and vali-
date a large-scale cryopreserved cell bank (sufficient to 
complete screening of the full compound collection). The 
subsequent cell bank used for screening was consistent over 
the >30 experimental runs needed to complete the HTS 
campaign and therefore allowed for true comparison of 
compound activity from run to run. As described in the 
methods as part of the screening protocol, cells were recov-
ered from cryovials and grown for a week, before an imag-
ing-based QC step to determine Wolbachia infection levels 
for screening. Figure 1 shows the consistency (in terms of 
Wolbachia infection levels) from two independent cryovial 
recoveries and is representative of the consistency seen 
across the entire screen.
With the cellular system established, we were able to 
begin optimization of the detection endpoints to be used 
within the screen. As previously mentioned, key for this 
project was to find chemical equity that displayed anti- 
Wolbachia activity over a 7-day treatment window, but with 
Figure 1. Control samples (with positive and negative Wolbachia infection) and QC results for the cells used in the validation of this 
assay, sourced from the single large-scale cryopreserved cell batch used for the full screen. (A) Cytoplasm texture score. The dotted 
line represents the threshold of the texture score above which cells are classed as infected (0.0028). (B) The percentage of cells 
that are classed as infected based on their cytoplasm texture score being above 0.0028. Comparison of the negative control with all 
Wolbachia-infected samples (positive control, validation runs 1 and 2) gives a Z′ of 0.67 and a signal to background of 5.6.
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negligible cytotoxic effect on the host C6/36 cells. In order 
to generate this multiparametric data at the primary screen-
ing stage, we established an assay using two markers: (1) 
Hoechst to stain DNA and enable quantification of C6/36 
host cells (2) anti-wBmPAL (detected through an Alexa 680 
secondary antibody) as a specific marker of Wolbachia. 
Using a specific marker of Wolbachia as opposed to the 
SYTO 11 protocol described previously20,21 enabled assay 
transfer to the acumen platform. While losing resolution 
from the confocal imaging method used previously at 
A·WOL, the acumen detection enabled a much faster acqui-
sition time per plate (reducing from 3 h to 20 min), with the 
additional benefit of whole-well scanning, rather than 
selected fields of view. This improved acquisition time 
made the full collection screen achievable within an accept-
able time frame. Both Alexa 488 (green fluorescence) and 
Alexa 680 (far red fluorescence) conjugated secondary anti-
bodies were tested as part of this assay development; how-
ever, we opted to move forward with the red-shifted 
fluorochrome in detection of the Wolbachia, in order to 
ensure maximum separation from the Hoechst emission 
spectra (461 nm). Past experience of fluorescent detection 
modalities applied to diversity screening has shown that 
higher-wavelength fluorochromes are preferable as they are 
farther away from the blue/green part of the spectra, where 
many cyclic molecules fluoresce.26 Experience within 
AstraZeneca (unpublished) has also shown that the artifacts 
generated through compound crystalization within imaging 
assays can be minimized by moving to higher wavelengths. 
A matrix of various concentrations of both primary and sec-
ondary antibody was tested in order to reduce the antibody 
concentrations where possible, allowing for a balance 
between cost and high-quality signal. Based on this optimi-
zation, a 1:2000 dilution of the primary antibody combined 
with a 1:400 dilution of the secondary antibody was chosen 
for the screen (Fig. 2), as this combination gave both the 
best Z′ and signal-to-background window.27
As further optimization of the screening protocol, we 
addressed both the wash regime used in the antibody stain-
ing and incubation conditions for the wBmPAL primary 
antibody (minimizing timing for each step wherever 
possible).
Further miniaturization of this assay was limited by the 
long-running challenge of achieving robust and consistent 
plate washing in a 1536-well format. Due to the multiple 
wash steps required within this assay, although we did 
explore newer technologies amenable to 1536-well washing 
(namely, the BlueCat centrifugal washer), we opted to 
remain in 384-well format in order to preserve consistency 
and accuracy.
Figure 2. (A) Wolbachia total area read on the acumen for matrix titration of primary and secondary antibody concentrations. 
The columns on the right include analysis of the titrations based on comparison of results from DMSO (Wolbachia positive control) 
and 5 µM doxycycline (Wolbachia negative control) treatment. (B) Operetta image (60× wide-field) of C6/36 (wAlbB) cells stained 
with Hoechst to identify the nuclei (blue) and antibody staining (primary antibody against wBmPAL with Alexa Fluor 680 secondary 
antibody) to identify the Wolbachia (red). (C) C6/36 (wAlbB) cells stained with Hoechst (blue) acquired on the acumen. (D) C6/36 
(wAlbB) cells stained with Wolbachia specific antibody (red) imaged on the acumen.
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Even though it was possible to generate both the specific 
Wolbachia readout and the Hoechst readout on the acumen, 
these reads would need to run sequentially on each well 
(due to excitation with different lasers). This was consid-
ered an approach to screening; however, we quickly dis-
counted this due to the time penalty incurred. Due to the 
consistency in cell number achieved through use of a single 
cryobank along with automated assay build (coupled to the 
intensity and consistency of Hoechst staining), we found 
that we were able to utilize a different modality for estab-
lishing a measured cell number, using the PerkinElmer 
Envision plate reader. Hence our finalized screening assay 
consisted of two independent readouts (on two independent 
platforms). This was made possible through the application 
of industrial-scale laboratory robotics (as described above 
and in the supplemental section).
The early decision with regard to the detection system of 
choice meant that assay development could be tailored to the 
acumen unit from the start. Test plates were imaged on the 
PerkinElmer Operetta during assay development (to aide 
understanding through highly resolved images) along with 
scanning on the acumen. This combined approach allowed 
fast decision making on population gating to apply to the acu-
men on-the-fly analysis. The screening assay is not config-
ured with high enough resolution to distinguish individual 
Wolbachia objects, and therefore objects needed to be gated 
based on maximum cluster size. Through the use of imaging 
during assay development, we determined that the largest 
Wolbachia clusters were around 100 μm × 40 μm; therefore, 
an upper gate was set on the acumen for object area (detected 
using the 680 nm channel) at 4000 μm2 (Fig. 3).
Once antibody staining and wash steps had been opti-
mized for detection on the acumen platform, the resultant 
protocol was transferred onto an Agilent BioCel 1800 plat-
form and configured as described earlier (Suppl. Fig. S3), 
enabling fully automated assay construction. Several rounds 
of optimization were undertaken in order to establish the 
optimum timing for plate entry onto the platform (otherwise 
known as “pacing time” or “tick time” for the protocol). 
The complexity of the overall assay procedure resulted in a 
finalized three-stage assay (Suppl. Fig. S2):
1. Manual 1-week recovery of cryopreserved cells in 
T225 cm2 flasks, followed by addition on day 7 into 
assay-ready test plates using a Multidrop Combi 
(Thermo Scientific) inside a class II biosafety cabi-
net, to ensure product protection.
2. On day 14, after 7 days of incubation with com-
pounds, formaldehyde fixation, Hoechst staining, 
and primary antibody staining of test plates was 
conducted on the Agilent BioCel 1800 unit 
(LEV[AQ: 2] extracted for safety reasons, to pre-
vent a localized buildup of formaldehyde vapor). 
On day 15, following a 12 h incubation of the pri-
mary antibody on the first plate, the second part of 
the BioCel 1800 protocol was initiated to carry out 
secondary antibody staining of the test plates.
3. From days 15 to 17, depending on the number of test 
plates in the batch, the plates were transferred to the 
HighRes Microstar platform, where they were 
sequentially read on a PerkinElmer Envision (to 
capture the Hoechst endpoint), followed by acquisi-
tion of the Wolbachia area endpoint on the acumen. 
The acumen acquisition was split over two individ-
ual readers pooled on the HighRes Microstar plat-
form in order to maintain throughput. This was 
followed by analysis using Genedata Screener as the 
data became available.
Due to the complexity of the automated protocol and the 
fact that assay runs were interleaved (in order to progress 
through the compound collection in a timely fashion), it 
was important to consider error recovery strategies. Assay 
plates had been shown to remain relatively stable if left for 
extended periods in PBS during the protocol; however, 
deterioration in assay quality was observed if fixative or 
permeabilization steps extended beyond the optimized time. 
The automated part of the protocol was configured so that a 
limited number of assay plates were released onto the 
robotic system at any one time (effectively forming a series 
of mini-batches). This phased-release strategy was 
employed in order to mitigate against potential large-scale 
loss of test plates due to unforeseen automation crashes.
Figure 3. (A) Operetta image 
(4× objective) of 384-well plate 
containing C6/36 (wAlbB) cells 
infected with Wolbachia. Primary 
antibody against wBmPAL with 
Alexa Fluor 680 secondary antibody. 
White box denotes Wolbachia clump. 
(B) Zoomed view into area denoted 
by white box in (A) showing 
Wolbachia clump with measuring 
lines. (C) Corresponding acumen 
2D fluorescence intensity plot of a 
Wolbachia clump.
8 SLAS Discovery 00(0)
With the assay system established, along with the screen-
ing procedure (including all automation protocols), valida-
tion of the assay for HTS was performed as described earlier. 
Validation showed the assay to perform well and established 
good agreement between occasion 1 and occasion 2 of the 
validation compound set. The mean of the differences in 
anti-Wolbachia activity fell close to the zero line when plot-
ted as a Bland-Altman28 (difference) plot with ±1 standard 
deviation lines at less than 14% variance (Fig. 4).
In addition to the validation data against the AstraZeneca 
validation set, concordance with IC50 data generated 
 historically from A·WOL was very good (Fig. 5A–D), 
Figure 4. Bland-Altman plot representing the variance in anti-Wolbachia activity between occasion 1 and occasion 2 testing the 
AstraZeneca validation set of compounds. The average difference in percent effect between paired results lies close to 0 (1.38) 
and 1*standard deviation is less than 14%. Darker colored points represent those with average activity ≥80% (the cutoff for active 
compounds in the screen).
Figure 5. Concordance testing 
of IC50 values for anti-Wolbachia 
activity and host cell toxicity across 
a set of 20 compounds from the 
A∙WOL drug discovery program. 
(A) Anti-Wolbachia IC50 values 
in A·WOL legacy screens versus 
acumen screen at AstraZeneca. (B) 
Toxicity IC50 values in legacy versus 
EnVision screen at AstraZeneca. (C) 
acumen anti-Wolbachia IC50 values 
for occasion 1 versus occasion 2 in 
the AstraZeneca screen. (D) EnVision 
toxicity IC50 values for occasion 1 
versus occasion 2 in the AstraZeneca 
screen.
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building further confidence in the assay as robust enough to 
move to a full HTS campaign. Figure 5A shows a strong 
agreement in anti-Wolbachia IC50 values between the acu-
men assay and legacy A·WOL assays (Spearman two-tailed 
correlation—where a coefficient [r value] of 1 is a perfect 
agreement; r = 0.9405, p < 0.0001). Doxycycline reported 
consistent IC50 values of 17.8 nM in the acumen assay 
(mean, n = 14 spread across two separate experimental 
runs) and 16 nM from A·WOL legacy assays (median from 
396 assays). Figure 5B shows a similar strong agreement in 
host cell toxicity between the A·WOL legacy data and those 
from the EnVision (r = 0.856, p < 0.0001). To add further 
confidence to the robustness of the screening assay, Figure 
5C,D shows the statistical agreement of the IC50 values 
over 2 different experimental occasions (r > 0.99, p < 
0.0001).
With each plate taking 22 min to read on the acumen 
(Wolbachia analysis) following the read on the EnVision 
(toxicity analysis), the planned batch size of 100–150 plates 
per day would take approximately 28 h to complete—with 
two acumen units employed in a pooled fashion on the 
HighRes Microstar automation platform. In order to carry 
out multiple runs per week (ideally four) and to allow for 
downtime, it was important to establish stability of the 
assay signal over an extended time frame. The AstraZeneca 
validation set of compounds (described earlier) was res-
canned, 7 days after the initial read (having stored the plates 
sealed at 4 °C). The Wolbachia signal remained consistent 
over this 7-day period (Suppl. Figs. S5 and S6).
The development of an HTS-compatible phenotypic 
assay enabled the screening of ~1.3 million compounds 
from the AstraZeneca collection with a resultant hit rate of 
2.36% (Fig. 6)—following annotation against the Hoechst 
measure of ≤60% cytotoxic effect on the C6/36 host cell 
line the final hit rate was reduced to 1.56% (20,255 
compounds). These hits were clustered by structure and 
rationalized down before subsequent confirmation, though 
the assay described here is in IC50 format and progressed 
through further cascade assays (both within AstraZeneca 
and within A·WOL) in order to build more annotation 
against the chemistry. Details of the completion, follow-up 
studies, and subsequent identification of five series of fast-
acting macrofilaricides have been presented in Clare et al. 
(2019).23
The combination of academic expert knowledge in a par-
ticular disease area with expertise in industrial-scale HTS is 
a model that other groups are now beginning to implement; 
however, the tight integration of A·WOL staff embedded 
within the HTS Department at AstraZeneca for the duration 
of the screen optimization, validation, and ultimate execu-
tion is, to our knowledge, a step further than other partner-
ships. This collaborative public–private venture is certainly 
unique in the NTD space, and we believe it has brought 
unique learning to both sides.
The Discovery Sciences Department at AstraZeneca has 
a leading position as a group delivering the skills and capa-
bilities essential for early-phase drug discovery on an indus-
trial scale, integrated within one global department. The 
A·WOL consortium has a leading position in the field of 
research against anti-Wolbachia agents, with specific bio-
logical tools such as the C6/36 (wAlbB) Wolbachia-infected 
cell line being instrumental to the HTS described. 
Combining the skills, resources, and expertise of both orga-
nizations was required in order to build, validate, and exe-
cute the complex screen described here.
The output from the screening activity described has 
identified novel chemical starting points from the 
AstraZeneca compound collection, resulting in the identifi-
cation of five series of novel fast-acting macrofilaricides,23 
allowing for the potential of an improved medication 
Figure 6. Frequency plot of primary 
HTS results across the 1.3 million 
compounds screened. The dotted 
line shows the cutoff used in the 
screen to select hits (≥80% activity 
as measured by total Wolbachia area). 
The distribution can be seen centered 
around zero with a tail leading out 
toward the left (active compounds). 
The proportion of compounds falling 
beyond the cutoff line shown is 2.36% 
of the total compounds tested.
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against both LF and onchocerciasis. These starting points 
for discovery will form the basis of future publications spe-
cifically addressing the discovery process from hit through 
to leads and optimized drug candidates.21,22
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